AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANATARA LIFESCIENCES LTD

0.011

-0.028-71.79%

Volume:29.99M

Turnover:362.97K

Market Cap:2.35M

PE:-1.05

High:0.020

Open:0.020

Low:0.010

Close:0.039

Loading ...

Overview Company News Filings

Anatara Lifesciences Says Phase Two Trial Unlikely to Achieve Primary Endpoint; Shares Fall 74% to All-Time Low

MT Newswires Live

BRIEF-Anatara Lifesciences Seeks Trading Halt Pending Announcement Regarding Update On Phase II Garp-Ibs Trial

Anatara Lifesciences Ltd - Seeks Trading Halt Pending Announcement Regarding Update on Phase Ii Garp-Ibs Trial

THOMSON REUTERS

Anatara Lifesciences Receives Australian Patent for Gastrointestinal Product; Shares Fall 8%

MT Newswires Live

BRIEF-Anatara Lifesciences Says Australian Patent Granted For GARP Product

Anatara Lifesciences Ltd - Australian Patent Granted for Garp Product

THOMSON REUTERS

Anatara Lifesciences Ltd-Share Purchase Plan Results

THOMSON REUTERS

Anatara reaches required level for recruitment in trial for IBS treament

The Market Herald

Anatara Lifesciences Ltd-Share Purchase Plan Shareholder Letter

THOMSON REUTERS

Anatara Lifesciences Ltd-Update - Proposed Issue of Securities - Anr

THOMSON REUTERS

Anatara Lifesciences Ltd-Successful Placement of $660K and Share Purchase Plan

THOMSON REUTERS

BRIEF-Anatara Lifesciences Seeks Trading Halt

Anatara Lifesciences Recruitment for Irritable Bowel Syndrome Trial Ongoing

MT Newswires Live

5 pharma & biotech stocks on the move in September

Anatara Lifesciences Ltd-European Patent Granted for Garp Product Addendum

THOMSON REUTERS

BRIEF-Anatara Lifesciences Says European Patent Granted For GARP Product

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/ANR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ANR.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANR.AU\",,,,,undefined,":{"symbol":"ANR.AU","market":"AU","secType":"STK","nameCN":"ANATARA LIFESCIENCES LTD","latestPrice":0.011,"timestamp":1741583520000,"preClose":0.039,"halted":0,"volume":29986217,"delay":0,"changeRate":-0.717949,"change":-0.028,"floatShares":125359802,"shares":213383727,"eps":-0.010438,"lyrEps":-0.009673,"pbRate":1.73,"amount":362970,"amplitude":0.25641,"volumeRatio":2175.562768,"dividePrice":0,"prevYearClose":0.047,"fiveDayClose":0.042,"twentyDayClose":0.057},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANR.AU\",,,,,undefined,":{"symbol":"ANR.AU","floatShares":125359802,"roa":"-76.07%","roe":"-147.32%","lyrEps":-0.009673,"volumeRatio":2175.562768,"shares":213383727,"dividePrice":0,"high":0.02,"amplitude":0.25641,"preClose":0.039,"low":0.01,"week52Low":0.01,"pbRate":"1.73","psRate":"9.37","week52High":0.073,"institutionHeld":0,"latestPrice":0.011,"committee":0.352588,"eps":-0.010438,"divideRate":0,"volume":29986217,"delay":0,"ttmEps":-0.010438,"open":0.02,"prevYearClose":0.047,"prevWeekClose":0.039,"prevMonthClose":0.042,"prevQuarterClose":0.047,"fiveDayClose":0.042,"twentyDayClose":0.057,"sixtyDayClose":0.046},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANR.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANR.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518697342","title":"Anatara Lifesciences Says Phase Two Trial Unlikely to Achieve Primary Endpoint; Shares Fall 74% to All-Time Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2518697342","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518697342?lang=en_us&edition=fundamental","pubTime":"2025-03-10 13:11","pubTimestamp":1741583512,"startTime":"0","endTime":"0","summary":"Anatara Lifesciences  said it is unlikely to achieve a statistically significant improvement in irritable bowel syndrome severity scoring system when compared to placebo in the second stage of the phase two Gastrointestinal ReProgramming-IBS trial based on preliminary analysis, according to a Monday Australian bourse filing.It said the second stage of the trial moved into the database lock process after all participants completed the mandatory two-week follow-up period.The final fully assessable number of participants has been reduced to 62 from 71 after the assessment of participant numbers for both compliance and entry criteria.The second stage included a planned extension of the phase two trial, following the successful completion of stage 1 which reported on 20 patients with a greater than 50% reduction in IBS symptoms and with a safety profile confirmed.It added that its planned anti-obesity in-vivo pre-clinical experiments are now underway following agreements with the University","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","ANR.AU","BK7067"],"gpt_icon":0},{"id":"2517972605","title":"BRIEF-Anatara Lifesciences Seeks Trading Halt Pending Announcement Regarding Update On Phase II Garp-Ibs Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2517972605","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517972605?lang=en_us&edition=fundamental","pubTime":"2025-03-06 09:37","pubTimestamp":1741225061,"startTime":"0","endTime":"0","summary":"BRIEF-Anatara Lifesciences Seeks Trading Halt Pending Announcement Regarding Update On Phase II Garp-Ibs TrialMarch 6  - Anatara Lifesciences Ltd ANR.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT REGARDING  UPDATE ON PHASE II GARP-IBS TRIALFurther company coverage: ANR.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO16D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2517227539","title":"Anatara Lifesciences Ltd -  Seeks Trading Halt Pending Announcement Regarding  Update on Phase Ii Garp-Ibs Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2517227539","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517227539?lang=en_us&edition=fundamental","pubTime":"2025-03-06 06:03","pubTimestamp":1741212213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO16D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2507574784","title":"Anatara Lifesciences Receives Australian Patent for Gastrointestinal Product; Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507574784","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507574784?lang=en_us&edition=fundamental","pubTime":"2025-01-29 10:43","pubTimestamp":1738118581,"startTime":"0","endTime":"0","summary":"Anatara Lifesciences  received a patent for its Gastrointestinal ReProgramming   product, under the invention title \"Gastrointestinal Health Composition,\" according to a Tuesday filing with the Australian bourse.The intellectual property protection, granted by the Australian Patent Office, has a 20-year term from Oct. 9, 2020, to Oct. 9, 2040, the filing said.The GaRP product is a complementary medicine designed to tackle the root causes of chronic gastrointestinal conditions like irritable bowel syndrome and inflammatory bowel disease, per the filing.Its shares fell 8% in afternoon trade Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","ANR.AU","XJO.AU","BK7508","XKO.AU","BK7067"],"gpt_icon":0},{"id":"2506530875","title":"BRIEF-Anatara Lifesciences Says Australian Patent Granted For GARP Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2506530875","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506530875?lang=en_us&edition=fundamental","pubTime":"2025-01-28 09:03","pubTimestamp":1738026192,"startTime":"0","endTime":"0","summary":"BRIEF-Anatara Lifesciences Says Australian Patent Granted For GARP ProductJan 28 (Reuters) - Anatara Lifesciences Ltd ANR.AX:AUSTRALIAN PATENT GRANTED FOR GARP PRODUCTFurther company coverage: ANR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3ON170:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","ANR.AU"],"gpt_icon":0},{"id":"2506531430","title":"Anatara Lifesciences Ltd - Australian Patent Granted for Garp Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2506531430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506531430?lang=en_us&edition=fundamental","pubTime":"2025-01-28 07:45","pubTimestamp":1738021548,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3ON170:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2492374474","title":"Anatara Lifesciences Ltd-Share Purchase Plan Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2492374474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492374474?lang=en_us&edition=fundamental","pubTime":"2024-12-20 09:23","pubTimestamp":1734657801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nTUE5M0LKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ANR.AU"],"gpt_icon":0},{"id":"2488185022","title":"Anatara reaches required level for recruitment in trial for IBS treament","url":"https://stock-news.laohu8.com/highlight/detail?id=2488185022","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488185022?lang=en_us&edition=fundamental","pubTime":"2024-12-04 10:26","pubTimestamp":1733279160,"startTime":"0","endTime":"0","summary":"Anatara Lifesciences Ltd  has enrolled 60 participants for Stage 2 of its key trial to assess candidate GaRP  for the treatment of IBS .Among these 60 are more than 25 high potential participants in the final screening process.Anatara had intended to complete enrollments by the end of 2024, and with the participant level at the required level for Stage 2, no more recruitment will be occurring beyond December 13 – although the screening process will continue.Participants have been recruited across four sites across the eastern mainland states of Australia and Adelaide.Anatara’s Executive Chair Dr. David Brookes said the trial recruitment was continuing at a pleasing rate.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/anatara-reaches-required-level-for-recruitment-in-trial-for-ibs-treament-2024-12-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","ANR.AU","BK7508"],"gpt_icon":0},{"id":"2486832689","title":"Anatara Lifesciences Ltd-Share Purchase Plan Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2486832689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486832689?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:31","pubTimestamp":1732656676,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nTUE2TS8XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ANR.AU"],"gpt_icon":0},{"id":"2483355315","title":"Anatara Lifesciences Ltd-Update - Proposed Issue of Securities - Anr","url":"https://stock-news.laohu8.com/highlight/detail?id=2483355315","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483355315?lang=en_us&edition=fundamental","pubTime":"2024-11-15 14:20","pubTimestamp":1731651651,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUE5X1NXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2483350612","title":"Anatara Lifesciences Ltd-Successful Placement of $660K and Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2483350612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483350612?lang=en_us&edition=fundamental","pubTime":"2024-11-15 07:59","pubTimestamp":1731628776,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUE7W263P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2483061295","title":"BRIEF-Anatara Lifesciences Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2483061295","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483061295?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:58","pubTimestamp":1731452325,"startTime":"0","endTime":"0","summary":"BRIEF-Anatara Lifesciences Seeks Trading HaltNov 13 (Reuters) - Anatara Lifesciences ANR.AX:ANATARA LIFESCIENCES SEEKS TRADING HALT PENDING ANNOUNCEMENT PROPOSED CAPITAL RAISINGFurther company coverage: ANR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MJ1NM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2476496517","title":"Anatara Lifesciences Recruitment for Irritable Bowel Syndrome Trial Ongoing","url":"https://stock-news.laohu8.com/highlight/detail?id=2476496517","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476496517?lang=en_us&edition=fundamental","pubTime":"2024-10-18 09:11","pubTimestamp":1729213887,"startTime":"0","endTime":"0","summary":"Anatara Lifesciences  said recruitment for the second stage of its GaRP product trial for irritable bowel syndrome is progressing with around 40 participants enrolled, according to a Thursday filing with the Australian Securities Exchange.The target participant number for the trial is 60 to 100, the filing said.The company added two sites in South Australia and Queensland to broaden participation, aiming to complete recruitment in the fourth quarter, according to the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","ANR.AU","XJO.AU","BK7508","XKO.AU","BK7067"],"gpt_icon":0},{"id":"2474239522","title":"5 pharma & biotech stocks on the move in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2474239522","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474239522?lang=en_us&edition=fundamental","pubTime":"2024-10-09 09:05","pubTimestamp":1728435934,"startTime":"0","endTime":"0","summary":"The Pharma & Biotech market had a relatively positive month with 41.5% of the coverage universe posting positive share price movements for the month of September. Over the 12-months to 30 September 2024 there has been some strong movements in the Pharma & Biotech universe with the share prices of 18 companies increasing by 100%+ with the best performer being Clarity Pharmaceuticals, whose share price has increased 618.5% over the 12-month period. Cannabis companies saw a renaissance during the month with the two biggest gainers in September both operating in the cannabis market.Below we take a look at 5 Pharma & Biotech companies whose share prices rallied in September.Subsequent to September-end, the Company announced a Non-Renounceable Entitlement Offer to raise ~$6.25 million . The Offer includes an Entitlement Offer that provides eligible shareholders the opportunity to subscribe for 1 new share for every 3 shares held at a price of 4 cents per share and 1 free attaching option for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/5-pharma-biotech-stocks-on-the-move-in-september-2024-10-09","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/5-pharma-biotech-stocks-on-the-move-in-september-2024-10-09","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7508","GARP","LU2637428348.USD","BK4585","4DX.AU","GARP.AU","BK4208","CMS","IBD","LU2346227817.USD","BK7067","BK7094","BK7502","BK7048","CAN.AU","BK7096","BK4588","EZZ.AU","ANR.AU","AGH.AU"],"gpt_icon":0},{"id":"2472382362","title":"Anatara Lifesciences Ltd-European Patent Granted for Garp Product Addendum","url":"https://stock-news.laohu8.com/highlight/detail?id=2472382362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472382362?lang=en_us&edition=fundamental","pubTime":"2024-10-01 08:17","pubTimestamp":1727741873,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241001:nTUE6V4KXL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2468942196","title":"BRIEF-Anatara Lifesciences Says European Patent Granted For GARP Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2468942196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468942196?lang=en_us&edition=fundamental","pubTime":"2024-09-20 15:35","pubTimestamp":1726817702,"startTime":"0","endTime":"0","summary":"Sept 20 (Reuters) - Anatara Lifesciences Ltd   :   * EUROPEAN PATENT GRANTED FOR GARP PRODUCTFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANR.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":1,"totalSize":18}]}}